МОЛЕКУЛЯРНЫЕ МИШЕНИ В ПРОФИЛАКТИКЕ И ЛЕЧЕНИИ ГИПЕРПЛАЗИИ И РАКА ПРЕДСТАТЕЛЬНО...Игорь Шадеркин
МОЛЕКУЛЯРНЫЕ МИШЕНИ В ПРОФИЛАКТИКЕ И ЛЕЧЕНИИ ГИПЕРПЛАЗИИ И РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
НИИ МОЛЕКУЛЯРНОЙ МЕДИЦИНЫ ММА им.И.М.СЕЧЕНОВА
Зам. директора по науке профессор КИСЕЛЕВ В.И.
МОЛЕКУЛЯРНЫЕ МИШЕНИ В ПРОФИЛАКТИКЕ И ЛЕЧЕНИИ ГИПЕРПЛАЗИИ И РАКА ПРЕДСТАТЕЛЬНО...Игорь Шадеркин
МОЛЕКУЛЯРНЫЕ МИШЕНИ В ПРОФИЛАКТИКЕ И ЛЕЧЕНИИ ГИПЕРПЛАЗИИ И РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
НИИ МОЛЕКУЛЯРНОЙ МЕДИЦИНЫ ММА им.И.М.СЕЧЕНОВА
Зам. директора по науке профессор КИСЕЛЕВ В.И.
Навчальний курс: «Молекулярна онкологія, патологія та генетика»
Медична лабораторія CSD спільно з Center for research and education of translational biology and medicine (www.tbm.center ) запускає безкоштовний курс навчальних лекцій для усіх бажаючих.
Презентация представлена на сателитный симпозиум в рамках ежегодного конгресса Армянской Ассоциации Урологов в октябре 2010 года. Спонсорская поддержка представительства компании Пфайзер в Армении,- Левон Кантарджян. Использованы материалы Пятого Европейского Симпозиума по Раку Почки, Лондон май 2010 года.
This document lists the achievements and awards received by Goodrich Global Pte Ltd from 2011 to 1996. Some of the highlights include being awarded The Most Valuable Company in 2011 in Hong Kong and receiving the Singapore Quality Class Certification in multiple years. The company was also recognized in various Enterprise 50 Awards and Singapore Small Medium Enterprise 500 Rankings during this period.
The document summarizes a Goodrich staff retreat held in Beijing from March 19-21, 2010 which included 140 staff from Hong Kong and China branches. The retreat included a karaoke night with a long service award ceremony, visits to the Great Wall and Beijing Olympic Park, and entertainment events like dancing and a fashion show. The retreat aimed to build camaraderie among Goodrich staff through social activities in Beijing.
We will be the most successful global supplier of interior decorative products. We are committed to continuous improvement in providing innovative products and service excellence to our customers. Our core values include teamwork, integrity, delighting customers, staff commitment, and continuous improvement.
Managing situations There is a deep thirst for progress and an inclination towards perfection within all of us. But somehow we are not able to bring that theory into practice and we are left stranded, at a loss looking for an anchor, a support, a direction which will help us take a step forward. During such challenging times, when life appears suffocating and difficult we don’t open up to others, not sure whether they will genuinely understand, help or mock at us. At times like these we feel a dire need for some guidance, direction which can channelise our thoughts to positivity and inspire us to become a master of the situation. This is for those people who want to make their own self progress and thereby better fulfill their purpose of life. Prajapita Brahma kumaris Ishwaria vishwa vidyalaya is an international Spiritual Organization dedicated to the service of humanity. It imparts spiritual knowledge and raja yoga meditation. With headquarters in mount Abu, this organization has more than 6000 branches spread over 82 countries. It is affiliated to the UN as an NGO and also has consultative status with the UNICEF and UN’s Social and Economic Council. The author of this presentation is follower of Brahmakumaris. Should you have any queries or even questions you can feel free to contact him at vihumanrelations@gmail.com To know more about the organization please visit Website : www.bramhakumaris.com
Goodrich provides a variety of interior furnishing options including wallcoverings, carpet, fabric, and flooring. The document discusses wallcoverings and carpet in more detail, highlighting their benefits such as allowing for self-expression, brightening rooms, and being durable and easy to maintain. Key information about Goodrich's product range and regional sales offices is also provided.
Таргетная терапия гормонорезистентного рака предстательной железыoncoportal.net
Таргетная терапия при раке простаты - важный и актуальный вопрос. В статье "Таргетная терапия гормонорезистентного рака предстательной железы" (И.В. Чернышев, А.А. Жернов, Д.В. Перепечин, НИИ урологии Минздравсоцразвития РФ, Москва) размещенной в журнале "Экспериментальная и клиническая урология" (Номер №1, 2012) рассматриваются текущие достижения мировой медицины
Навчальний курс: «Молекулярна онкологія, патологія та генетика»
Медична лабораторія CSD спільно з Center for research and education of translational biology and medicine (www.tbm.center ) запускає безкоштовний курс навчальних лекцій для усіх бажаючих.
Презентация представлена на сателитный симпозиум в рамках ежегодного конгресса Армянской Ассоциации Урологов в октябре 2010 года. Спонсорская поддержка представительства компании Пфайзер в Армении,- Левон Кантарджян. Использованы материалы Пятого Европейского Симпозиума по Раку Почки, Лондон май 2010 года.
This document lists the achievements and awards received by Goodrich Global Pte Ltd from 2011 to 1996. Some of the highlights include being awarded The Most Valuable Company in 2011 in Hong Kong and receiving the Singapore Quality Class Certification in multiple years. The company was also recognized in various Enterprise 50 Awards and Singapore Small Medium Enterprise 500 Rankings during this period.
The document summarizes a Goodrich staff retreat held in Beijing from March 19-21, 2010 which included 140 staff from Hong Kong and China branches. The retreat included a karaoke night with a long service award ceremony, visits to the Great Wall and Beijing Olympic Park, and entertainment events like dancing and a fashion show. The retreat aimed to build camaraderie among Goodrich staff through social activities in Beijing.
We will be the most successful global supplier of interior decorative products. We are committed to continuous improvement in providing innovative products and service excellence to our customers. Our core values include teamwork, integrity, delighting customers, staff commitment, and continuous improvement.
Managing situations There is a deep thirst for progress and an inclination towards perfection within all of us. But somehow we are not able to bring that theory into practice and we are left stranded, at a loss looking for an anchor, a support, a direction which will help us take a step forward. During such challenging times, when life appears suffocating and difficult we don’t open up to others, not sure whether they will genuinely understand, help or mock at us. At times like these we feel a dire need for some guidance, direction which can channelise our thoughts to positivity and inspire us to become a master of the situation. This is for those people who want to make their own self progress and thereby better fulfill their purpose of life. Prajapita Brahma kumaris Ishwaria vishwa vidyalaya is an international Spiritual Organization dedicated to the service of humanity. It imparts spiritual knowledge and raja yoga meditation. With headquarters in mount Abu, this organization has more than 6000 branches spread over 82 countries. It is affiliated to the UN as an NGO and also has consultative status with the UNICEF and UN’s Social and Economic Council. The author of this presentation is follower of Brahmakumaris. Should you have any queries or even questions you can feel free to contact him at vihumanrelations@gmail.com To know more about the organization please visit Website : www.bramhakumaris.com
Goodrich provides a variety of interior furnishing options including wallcoverings, carpet, fabric, and flooring. The document discusses wallcoverings and carpet in more detail, highlighting their benefits such as allowing for self-expression, brightening rooms, and being durable and easy to maintain. Key information about Goodrich's product range and regional sales offices is also provided.
Таргетная терапия гормонорезистентного рака предстательной железыoncoportal.net
Таргетная терапия при раке простаты - важный и актуальный вопрос. В статье "Таргетная терапия гормонорезистентного рака предстательной железы" (И.В. Чернышев, А.А. Жернов, Д.В. Перепечин, НИИ урологии Минздравсоцразвития РФ, Москва) размещенной в журнале "Экспериментальная и клиническая урология" (Номер №1, 2012) рассматриваются текущие достижения мировой медицины
ИСПОЛЬЗОВАНИЕ “ЭНОАНТА" ДЛЯ КОРРЕКЦИИ АНЕМИИ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ ( КЛИ...Александр Ст
Среди хронических болезней человечества онкология занимает второе место в мире по смертности (после сердечно-сосудистых заболеваний). Основная статегия лечения онкологических больных в прошлом веке была направлена на полное излечение, т.е. на полную деструкцию первичной опухоли. Такая стратегия однозначно определяла и направленность научных исследований, в рамках которых создавались противоопухолевые препараты преимущественно цитотоксического действия. Основная мишень действия таких препаратов - опухолевая клетка. Основная цель - убить эту клетку любой ценой [6]. Переход в третье тысячелетие характеризовался формированием новой идеологии, в рамках которой на первое место выходит увеличение продолжительности жизни в сочетании с улучшением качества жизни онкологических больных [8]. Такие существенные изменения в стратегии лечения онкологических больных обусловлены как низкой эффективностью противоопухолевой терапии при лечении местно-распространенных и диссеминированных форм злокачественных новообразований, так и высокой степенью токсичности противоопухолевой терапии в отношении нормальных органов и тканей.
Известно, что спектр токсических проявлений противоопухолевой терапии очень широк (ВОЗ классифицируют более 20 видов побочных действий противоопухолевой химио- и лучевой терапии), а степень проявлений может быть очень значительной.
Our preliminary experimental study showed that food concentrate of grape polyphenols “Enoant” provided significant protective effect on Cisplatinum-induced hemotoxicity increasing a red blood cell production. The first course of cancer chemotherapy was made when the hemoglobin level reached 89.9+1.5 g/l. Before next schedule of anticancer treatment the patients received “Enoant” (total dose of grape polyphenols was 5 g), that resulted in more than 20% increase of hemoglobin level (p<0.05) up to 104.4+5.5 g/l. Using of “Enoant” gave the possibility to carried out the cancer chemotherapy treatment in time and without any dose reduction. The obtained results showed that “Enoant” is effective, safe and good accepted by patients stimulator of erythropoesis, that allows to recommend it for wide application in therapy of cancer patients with anemia of different genesis.
diagnosis and treatment of metastatic prostate cancer, as Timely diagnosis and treatment of this disease are still unsolved clinical problem. As of 2011, disease the most prostate cancer in Russia was 10.7% (40 thous. of new cases) of the male population, and in 60% of cases the disease diameter gnostirovali late (III-IV) step, the process is inevitable when the active growth and spread of metastases. Methods anatomical imaging in the diagnosis of the disease have low sensitivity and specificity. Methods for metabolic imaging using as a marker of prostate specific antigen (PSA), and ineffective. As a marker for diagnosing and Metastatic prostate cancer is invited to consider prostate-specific membrane antigen (PSMA). Abroad in clinical trials the most promising diagnostic radiopharmaceuticals based on small peptide molecules, modification infected urea, which have the highest affinity for PSMA. A distinguishing feature of these compounds is their favorable pharmacokinetics and a high long-term accumulation in the tumor and metastases, rapid excretion from the body. metastatic prostate cancer, prostate specific membrane antigen, radiopharmaceuticals. Citation: Vlasova O., German KE, Krylov VV, Petrov VM, Epstein NB New radiopharmaceuticals for diagnostics and metastatic prostate cancer based on prostate-specific membrane antigen inhibitors. Bulletin of Medical Sciences. 2015; 70 (3): 360-365. Doi: 10.15690 / vramn.v70i3.1334
16. Пути воздействия на НЕ R-2 рецептор Herceptin Идея нейтрализовать активность рецептора HER-2 привела к созданию моноклонального антитела , направленного специфически против этого рецептора Моноклональное антитело, воздействует на наружную часть рецептора препятствует его активации
21. HERCEPTIN Профилактическое лечение Уменьшение частоты рецидивов, улучшение выживаемости Улучшение на 52% Улучшение на 46% Улучшение на 40%
22. Herceptin: 10- летнее влияние на частоту метастатического рака молочной железы Weisgerber-Kriegl et al. ASCO 2008 abstract 6589
23.
24.
25. Пути воздействия на НЕ R-2 рецептор Лапатиниб ( Tykerb) Низко—молекулярное вещество Угнетение внутриклеточной ферментативной части HER -2 рецептора Остановка передачи сигналов, полученных снаружи клетки
26. Лапатиниб присоединяется к внутри-клеточной части рецептора, прекращая процесс передачи сигналов к делению в ядро опухолевой клетки Ligands HER-2 рецептор Other ErbB Деление Выживание клеток Лапатиниб PI3K/Akt pathway MAPK pathway (Ras/Raf/ MEK/ERK) PI3K/Akt pathway MAPK pathway (Ras/Raf/ MEK/ERK)
Targets and bullets in breast cancer This slide summarizes key ‘targets’ that may be of therapeutic relevance in breast cancer, along with the ‘bullets’ (therapeutics) available or under development (note: it is not an exhaustive diagram of all signaling pathways). The graphic focuses on the most clinically developed agents in breast cancer; additional agents include those listed below: ErbB1/2 TKI = HKI-272, BIBW 2992, PKI-166, EKB-569 Pan-ErbB TKI = caneritinib, BMS-599626 ErbB1/ErbB2/VEGFR TKI = XL647, AEE788 HSP90 inhibitors = CNF2024, IPI-504, AUY922, SNX5422 IGF-IR inhibitors (mAb or TKI) = CP-751871, EM164, IMC-A12, NVP-ADW742, Insm-18 HDAC inhibitors = LBH589, PXD101, NVP-LAQ824, depsipeptide, CI-994, MS-275 PI3K inhibitors = SF1126, BEZ235, XL147, XL765 Akt inhibitors = perifosine, XL418 mTOR inhibitors = rapamycin (sirolimus), deforolimus, flavopiridol Notes for presenter on lesser known agents shown on slide: Ertumaxomab (Trion Pharma) is a bi-specific antibody that stimulates an immune response on binding ErbB2 and CD3 Vorinostat = Zolinza ® , Merck Temsirolimus = Torisel ® , Wyeth Everolimus = Certican ® , Novartis Tanespimycin and alvespimycin are both in development by Kosan HDAC=histone deacetylase; TKI=tyrosine kinase inhibitor
Small molecules block signalling from inside the cell In contrast to monoclonal antibodies like trastuzumab, small molecule kinase inhibitors like Tykerb work from inside the cell. By blocking ErbB1 and ErbB2 receptor phosphorylation and activation, Tykerb prevents subsequent downstream signalling events in the ERK-1/2 and PI3K/Akt pathways, resulting in cell growth arrest and/or apoptosis 1,2 . Konecny et al. Cancer Res 2006; 66 :1630–9 Rusnak. Mol Cancer Ther 2001; 1 :85–94 Hegde et al. Mol Cancer Ther 2007; 6( 5):1629–40 Xia et al. Oncogene 2002; 21 (41):6255–63
Small molecules block signalling from inside the cell In contrast to monoclonal antibodies like trastuzumab, small molecule kinase inhibitors like Tykerb work from inside the cell. By blocking ErbB1 and ErbB2 receptor phosphorylation and activation, Tykerb prevents subsequent downstream signalling events in the ERK-1/2 and PI3K/Akt pathways, resulting in cell growth arrest and/or apoptosis 1,2 . Konecny et al. Cancer Res 2006; 66 :1630–9 Rusnak. Mol Cancer Ther 2001; 1 :85–94 Hegde et al. Mol Cancer Ther 2007; 6( 5):1629–40 Xia et al. Oncogene 2002; 21 (41):6255–63
NOTE: animated slide Tykerb acts intracellularly, directly and effectively inhibiting downstream signalling By inhibiting the tyrosine kinase activity of ErbB1 and ErbB2, [click] Tykerb effectively inhibits downstream signalling pathways activated by these receptors, as well as by receptors dimerizing with them (e.g. ErbB2–ErbB3 dimers).
VEGF expression by tumours is driven by many factors that are characteristic of tumours, including oncogene expression and hypoxia. VEGF also mediates the angiogenic effects of other angiogenic molecules, meaning that it has a central role in the control of tumour angiogenesis. Several mechanisms are involved in the regulation of VEGF gene expression. Hypoxia is important in vitro and in vivo . VEGF mRNA expression is rapidly and reversibly induced by exposure to low partial oxygen pressure in normal and transformed cultured cell types. VEGF mRNA is markedly induced in quiescent human keratinocytes when they are exposed to serum, EGF, TGF-ß, or keratinocyte growth factor. 1 Several oncogenes promote VEGF expression. For example kRAS , HRAS and HER2 upregulate VEGF and HPV-16 stimulates VEGF secretion. Wild-type p53 down-regulates VEGF transcription, and normally inhibits tumour growth. The mutated p53 protein has a reduced ability to down-regulate VEGF transcription, resulting in tumour cells that respond less to anti-angiogenic agents. 2 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727–39.
This slide summarises the proposed three-stage mechanism of action of Avastin. It has been proposed that anti-VEGF therapy exerts a ‘dynamic’ anti-angiogenic effect on tumour vasculature throughout the course of its use, with important effects observed early and continued later in treatment. Two early effects of anti-VEGF therapy include regression of existing tumour microvasculature 1–2 and normalisation of remaining tumour vasculature. 1,4,5 These effects indicate that Avastin may have efficacy in cancer therapy, including the potential to improve the delivery of concomitant chemotherapies. A third important effect of anti-VEGF therapy – inhibition of new tumour vasculature 3,4 – may be considered a ‘continued effect’ because it may contribute to additional benefits observed over longer periods of time. The continued inhibition of tumour neovascularisation suggests that use of Avastin until tumour progression can be an effective treatment strategy. VEGF = vascular endothelial growth factor References Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145–7. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102–11. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35–52. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671–80. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.